PRZOOM - /newswire/ -
Monrovia, CA, United States, 2010/11/24 - Carolyn Compton, will give a featured presentation on “Those Biomarkers Come from Biospecimens: Garbage In, Garbage Out” at GTCbio’s 3rd Oncology Biomarkers Conference on January.
Carolyn Compton, Director of the NCI Office of Biorepositories and Biospecimen Research will give a featured presentation on “Those Biomarkers Come from Biospecimens: Garbage In, Garbage Out” at GTCbio’s 3rd Oncology Biomarkers Conference on January 27-28, 2011 in San Diego, CA
Dr. Compton will discuss how human biospecimens of sufficient quality are the principal sources of molecular data from patients. They are needed to meet the demands of the state-of-the-art analysis technologies that are essential for the accurate identification of molecular targets for drug development, disease diagnosis, and prevention; characterization of biologic variations that determine drug efficacy and drug toxicity; identification of markers for susceptibility, screening, and reoccurrence; development of molecular-based disease taxonomies; elucidation of molecular mechanisms of disease; and validation of new therapeutics and diagnostics.
The increased molecular analysis capabilities of a technology-rich era have raised the bar for the quality of biospecimens to be analyzed and the biomolecular analytes (e.g., RNAs, DNA, chromatin, etc.) derived from them. Individual molecular species derived from the biospecimen must be of high, consistent quality to ensure that the molecular-analysis data is reliable. When the analytes (”biomarkers”) come from human biospecimens, the quality of the biospecimen itself is a precondition of derivative analyte quality.
Attendees will understand the following:
1) how pre-analytical variables change biospecimen molecular composition and quality;
2) how either can lead to misinterpretation of artifact as a biomarker;
2) how to approach a solution to these issues.
Dr. Compton currently holds several national and international leadership positions in professional organizations such as the College of American Pathologists, the Cancer and Leukemia Group B, the American Joint Committee on Cancer, and the American Society of Clinical Oncology. She is also a member of the editorial boards of Cancer, Biopreservation and Biobanking and Clinical Proteomics. In addition to human biospecimen science, her research interests include translational studies in colon cancer, pancreatic cancer and wound healing.
For more information visit gtcbio.com/.